3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
12
Tumor-Agnostic
6
Gastrointestinal
4
Genitourinary
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
258
Radiotherapy
147
Bevacizumab
142
Etoposide
68
Cyclophosphamide
68
Carboplatin
66
Magnetic Resonance Spectroscopy
58
Irinotecan
53
Cisplatin
52
Vincristine
45
Filgrastim
43
pembrolizumab
40
Radiosurgery
36
Nivolumab
36
Radiation
34
Topotecan
31
Doxorubicin
30
Specimen Handling
29
sargramostim
28
Lomustine
27
Erlotinib Hydrochloride
27
Peripheral Blood Stem Cell Transplantation
25
Carmustine
25
Thiotepa
24
Everolimus
23
Chemotherapy, Adjuvant
23
Surgical Procedures, Operative
22
Isotretinoin
22
Ipilimumab
22
Melphalan
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
alectinib
×
CNS
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts